The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
Prescription drug spending in Medicaid and other health programs has returned to the national policy debate. This analysis examines Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.
This issue brief provides an overview of the Medicare Part D prescription drug benefit market for 2022, with a primary focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2022.
In a commentary on KFF’s 27th employer health benefits survey, President and CEO Dr. Drew Altman discusses the obstacles employers face trying to control their health care costs, and the reasons why they’ve never been meaningful supporters of government cost-containment efforts. He predicts that premium increases expected next year could lead to a new wave of higher deductibles and other forms of cost sharing for the 155 million Americans who rely on employer coverage. Read…
The Medicare Chartbook includes data and background information critical to understanding the Medicare program and the challenges it faces in keeping up with the rising costs of health care and in ensuring the program s future financial security.
This paper, by Sara Rosenbaum, J.D., Director of the Center for Health Services Research and Policy at George Washington University, examines the procedures for resolving beneficiaries' grievances and appeals under the new Medicare drug benefit. It is one in a series commissioned by the Kaiser Family Foundation that analyzes issues surrounding the implementation of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and the proposed regulations. Issue Brief (.pdf)
Implications of The Medicare Modernization Act For States: Observations from a Focus Group Discussion with Medicaid Directors This report summarizes a discussion with a group of state Medicaid officials about the impact of the Medicare prescription drug benefit on state Medicaid programs. Report (.pdf)
National Survey of Pharmacists 2006: Full Topline Results These toplines provide additional findings from a 2006 national survey of pharmacists on their views and experiences on a wide range of health care issues. Toplines (.pdf)
This document includes the complete toplines from a survey of the public's attitudes regarding the health care agenda for Bush's second term and the new Congress in 2005. It assesses the relative priority placed on health-care concerns by the American public and also provides insight into public opinion on key issues likely to face the new Congress, such as implementing the Medicare drug law, controlling health care costs, reducing the nation’s uninsured population and reforming…
New Survey Assesses Senior's Views of Medicare Drug Law Seniors are most likely to say they would turn to their doctor, pharmacist, or the Medicare program, for help in making decisions about the new Medicare drug benefit set to begin Jan. 1, 2006, according to new data from the Kaiser Health Poll Report tracking survey. The tracking survey also provides updated tracking data on seniors’ knowledge and views of the new Medicare law. Foundation President…
In February, the Trump administration launched TrumpRx, a government website that provides prescription drug discounts to consumers. This brief examines issues that may impact consumers, especially those with private insurance, who access drug discounts through TrumpRx.
© 2026 KFF